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E M B O L I Z AT I O N

Treating Pulmonary
Arteriovenous
Malformations
What to do and what not to do.
BY JUSTIN M c WILLIAMS, MD, AND RIPAL T. GANDHI, MD

P

ulmonary arteriovenous malformations (AVMs)
represent direct connections between the pulmonary artery and vein. Although they can be
sporadic, approximately 70% of pulmonary AVMs
are associated with hereditary hemorrhagic telangiectasia
(HHT).1 If left untreated, patients can present with paradoxical embolization (stroke or brain abscess), dyspnea
and exercise intolerance, or pulmonary hemorrhage.2
Embolization has become the favored method of treatment. This article serves to provide recommendations
of what and what not to do in patients with pulmonary
AVMs, based partially on published literature and partially on our personal experience in treating a multitude
of these technically challenging lesions.
WHAT TO DO
Screen for HHT
Any patient with a pulmonary AVM has a high likelihood of HHT, and the presence of multiple pulmonary
AVMs is almost pathognomonic of HHT. Ask any patient
with pulmonary AVM the following two questions and
perform the following examination:
• Do you have nosebleeds? More than 95% of adult
patients with HHT have spontaneous and recurrent
nosebleeds (median age of onset, 12 years).
• Do any of your family members get frequent nosebleeds? Because HHT is autosomal dominant (it does
not skip generations), either the patient’s mother or
father is usually affected, and often other family members are as well.
Examine the lips, tongue, oral mucosa, and fingertips
for small red spots. Telangiectasias are present in > 90%
of adult patients with HHT, usually beginning in their 20s
and increasing with age.
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Any patient with a pulmonary AVM
has a high likelihood of HHT, and the
presence of multiple pulmonary AVMs
is almost pathognomonic of HHT.

If any one of the three examination findings is positive, HHT is possible/probable, and if any two or three are
positive, the diagnosis of HHT is definite, given that they
already have a pulmonary AVM. In this case, referral to the
closest HHT Center of Excellence (there are 22 in North
America and several in Europe) should be considered.
Think Before You Treat
Historically, a feeding artery diameter of 3 mm was considered to trigger embolization therapy for a pulmonary
AVM.2 Due to advancements in techniques and catheter
technology, we now have the capability to treat lesions
with feeding arteries as small as 1 mm. However, not all
of these small AVMs require treatment. Complications
of pulmonary AVMs < 2 mm are almost unheard of, and
complications from AVMs in the 2- to 3-mm size range are
uncommon.3 Treating asymptomatic AVMs with a feeding
artery of at least 3 mm is widely supported, as well as any
symptomatic AVM. Asymptomatic AVMs under 2 mm are
considered very low risk and are not typically treated. For
asymptomatic 2- to 3-mm AVMs, embolization is generally
recommended, but we often defer treatment in children
and adolescents (with the plan to embolize at age 18), and
in elderly patients.
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Figure 1. This figure shows a 45-year-old man with HHT and asymptomatic 3-mm left upper lobe pulmonary AVM detected
on routine screening. A left upper lobe angiogram demonstrates the AVM (A). Access to the left upper lobe artery was difficult, requiring a Judkins Right-4–shaped catheter. An angiogram through a 0.021-inch microcatheter demonstrates appropriate position at the proximal margin of the aneurysmal sac (B). Spot film demonstrating appropriate position of a MVP-3Q,
prior to deployment (C). Final angiography confirms complete occlusion of the AVM with a single device (D).

Finding the Treasure Is Easiest With a Map
The procedure should commence with a high-volume
angiographic run from the right or left pulmonary artery
through a pigtail catheter. The ideal angle is determined
by review of the preprocedure CT scan; if in doubt, a
30° to 40° contralateral oblique view opens and separates the pulmonary arteries most effectively. The best
sensitivity for detecting pulmonary AVMs will come
with imaging in full inspiration; however, this run will be
almost useless as a “smart mask” for actual guidance into
the target vessel. For intraprocedural guidance into the
AVM itself, it is often more useful to ask the patient to
“stop breathing” rather than to “take a breath in.”
Have the Right Stuff
Pulmonary AVM embolization is technically challenging because the constant movement of the heart and
lungs tends to dislodge carefully placed catheters; wires
tend to select the branch you do not want; and fear
(or anxiety) is common at the moment of coil or plug
release. For stability, we use a White Lumax catheter
set (Cook Medical), which consists of a long, 7-F angled
guide catheter to maintain stability in the parent artery
and an inner 5-F angiographic catheter for vessel selection. If the origin of the desired vessel is particularly
tortuous or difficult, a 5-F angled Glidecath (Terumo
Interventional Systems) can be helpful. A Judkins
Right-4 catheter (Merit Medical Systems, Inc.) is particularly effective for acute angled origins of the upper
or middle lobes (Figure 1). It is preferable to navigate
the angiographic catheter into the desired vessel using
careful rotation and advancement of the catheter itself,
checking the course with puffs of contrast. If this fails,
an angled Glidewire (Terumo Interventional Systems)
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Figure 2. This figure shows a 39-year-old man with HHT,
after coil embolization of left lower lobe pulmonary
AVM 5 years earlier. Initial angiography demonstrates
recanalization through the previously placed coils (A). After
deployment of a single MVP-5Q, the recanalized vessel is
completely occluded (B). The adjacent pulmonary artery
branches are spared.

can be used to select the desired vessel, being careful
not to push too aggressively.
Get Yourself Out There
Due to potential collateralization, AVM recanalization is common if embolization is performed too
proximally. Distal embolization, either at the very
distal aspect of the feeding artery4 or within the AVM
itself5 is desired to minimize recurrence of the lesion.
In AVMs with a large feeding artery, this can often
be accomplished using Amplatzer Vascular Plugs (St.
Jude Medical, Inc.) delivered through the 7-F guide
catheter. These are typically oversized by 30% to 50%,
with respect to the target vessel diameter. For intermediate-size AVMs, 0.035-inch coils can be delivered
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Figure 3. This figure shows a 32-year-old woman with HHT and history of brain abscess. Initial pulmonary angiography confirms a complex AVM in the right lower lobe (A). Proximal embolization was considered to be high risk for recanalization.
Control angiography after coiling of the distal portion of the anterior basilar segmental artery demonstrates persistent supply
from the proximal portion (B). After coiling of this branch, angiography of the lateral basilar segmental artery demonstrates
further supply to the AVM (C). Final angiography demonstrates complete occlusion of the AVM from its distal to proximal
extent (D). A total of 36 coils were used.

through a 4- or 5-F catheter, an Amplatzer Vascular
Plug 4 can be delivered through a 5-F angiographic
catheter, and MVP-7Q and MVP-9Q microvascular
plugs (Medtronic) can be delivered through 4- and 5-F
catheters, respectively. For small or tortuous AVMs,
distal embolization usually requires a microcatheter. It
is important to use a microcatheter size that is compatible with your desired embolic agent (a standard
microcatheter for standard microcoils or a high-flow
microcatheter for larger microcoils). Try to avoid
smaller microcatheters, which provide suboptimal
angiographic runs and can be easily misdirected into
tiny pulmonary sub-branches.
We have found the MVP-3Q and MVP-5Q to be very
useful for single-device occlusion of small AVMs. The
MVP-3Q occludes vessels up to 3 mm and is compatible with standard-size microcatheters, whereas the
MVP-5Q occludes vessels up to 5 mm and is compatible
with high-flow microcatheters. For complex AVMs, long
detachable coils can be used to embolize the AVM
nidus to prevent recanalization (Figure 2). We have
found that the standard and soft Interlock fibered
coils (Boston Scientific Corporation) provide a good
balance of rapid deployment, efficient occlusion, and
relatively low cost. Concerto coils (Medtronic) are
very soft, reducing pushback and making them useful when the microcatheter is tenuously positioned.
Other good detachable coil alternatives include Ruby
coils (Penumbra, Inc.) and Azur hydrocoils (Terumo
Interventional Systems). For pushable coils, the Nester
and MicroNester line of coils (Cook Medical) provide
inexpensive cross-sectional occlusion.
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Beware the Air (and the Clot)
An air embolism is a serious risk when treating pulmonary AVMs; any air passing into a pulmonary AVM
can pass directly into the left-sided circulation and from
there, into the brain, causing a transient ischemic attack
or worse. Prior to the procedure, nurses should be cautioned not to inject any air bubbles when the IV is started,
and an air filter should be placed if available. During the
procedure, blood should be aspirated prior to each injection, even with the microcatheter, to ensure a solid liquid
column within the catheter. Wires should be removed
either under saline within a basin or with a constant drip
of saline into the catheter hub. Although there is institutional variation, we choose to administer heparin to all
patients immediately after venous access to prevent clot
formation on the catheter during treatment.
WHAT NOT TO DO
Don’t Test Your Luck
The moment of delivery of the first coil is often one
of consternation. To minimize the stress, use a long,
detachable, and slightly oversized coil for the first coil,
and watch that it deforms as you push it out (suggesting ample wall contact) and that it is completely immobile prior to full deployment (suggesting secure position).
If there is any concern, simply recapture the coil and
choose a more appropriate size. Pushable coils can be
used behind the first coil, if desired, but the risk/reward
ratio greatly favors that the all-important first coil be
detachable. Alternatively, use a vascular plug, all of which
are detachable and secure if sized properly (if you are
unsure, use a larger size).

Don’t Skimp on the Embolic Agent
Recanalization occurs either by collateralization
around the embolic agent, or by flow resumption
directly through the embolic agent. To minimize the latter, create a tight coil pack composed of multiple coils,
and if in doubt, add more. If a porous plug, such as an
Amplatzer Vascular Plug, is used, backing it up with one
or two cheap pushable coils will help prevent recanalization through the plug. Polytetrafluoroethylene-lined
plugs, such as the MVP, can be a one-device solution
(Figure 3), but may not produce full occlusion if placed
in areas of tortuosity and can also be backed up with
coils in this instance.
Don’t Sacrifice Safety for Convenience
Being sure not to sacrifice safety is especially important when treating multiple lesions in one session
because radiation and contrast limits may come into
play. There is no shame in staging the procedure and
bringing the patient back on a different occasion to finish the job.
CONCLUSION
Treatment of pulmonary AVMs is challenging and
exhilarating. Proper planning and appropriate equipment, along with good working knowledge of what
(and what not) to do, will help optimize outcomes. n
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